Κυριακή 9 Δεκεμβρίου 2018

Experts canvass integrated solid waste management - Guardian Nigeria

Experts canvass integrated solid waste management  Guardian Nigeria

Environmentalists have called for integrated approach in management of e-waste and other consumer products containing Polybrominated Diphenyl Ethers, ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L4EBCQ

Experts canvass integrated solid waste management - Guardian Nigeria

Experts canvass integrated solid waste management  Guardian Nigeria

Environmentalists have called for integrated approach in management of e-waste and other consumer products containing Polybrominated Diphenyl Ethers, ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L4EBCQ

Dual exposure to smoking and household air pollution is associated with an increased risk of severe asthma in adults in Brazil

Abstract

Background

The relationship between smoking, household pollution, dual exposure and severity of asthma in adults has not been sufficiently studied. We examined and compared the effects of cigarette smoking, domestic wood burning pollution and dual exposure (tobacco and wood burning) upon asthma severity in adults.

Methods

This was a cross-sectional study performed with 452 individuals with mild to moderate asthma and 544 patients with severe asthma (previously untreated). Smoking and exposure to wood smoke were identified and quantified through questionnaires to evaluate current and/or previous exposure; objective determination of cigarette exposure was obtained through the measurement of urinary cotinine. Asthma control was evaluated through Asthma Control Questionnaire; and severity was classified according to the Global Initiative for Asthma criteria. Subjects were grouped according to exposure type into 4 groups: smokers, household pollution, dual-exposure and no-exposure. Chi square, Mann–Whitney, and Kruskal–Wallis tests were used for comparisons between groups.

Results

Out of 996 included individuals, 78 (7.8%) were exposed to cigarette smoking alone, 358 (35.9%) to household pollution alone, 155 (15.6%) to the two exposures combined and 405 (40.7%) were not exposed. Compared to unexposed individuals, exposure to household pollution resulted in poorer asthma control, higher proportion of severe asthma, and worse indicators of lung function. The double-exposed individuals were worse off in all the evaluated parameters, and they were significantly worse than subjects with single exposure to household air pollution in relation to asthma severity and lung function. These subjects were predominantly females, older, with longer residence time in rural areas, lower income and lower schooling levels. Multivariate analysis showed that exposure to household pollution and double exposure were predictive factors associated with lack of control and increased severity of asthma.

Conclusions

Exposure to household pollution is associated with poorer control, greater severity, and poorer pulmonary function; double-exposed individuals have a greater risk of severe asthma and decreased lung function than those exposed only to household pollution.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RLo4pX

Dual exposure to smoking and household air pollution is associated with an increased risk of severe asthma in adults in Brazil

Abstract

Background

The relationship between smoking, household pollution, dual exposure and severity of asthma in adults has not been sufficiently studied. We examined and compared the effects of cigarette smoking, domestic wood burning pollution and dual exposure (tobacco and wood burning) upon asthma severity in adults.

Methods

This was a cross-sectional study performed with 452 individuals with mild to moderate asthma and 544 patients with severe asthma (previously untreated). Smoking and exposure to wood smoke were identified and quantified through questionnaires to evaluate current and/or previous exposure; objective determination of cigarette exposure was obtained through the measurement of urinary cotinine. Asthma control was evaluated through Asthma Control Questionnaire; and severity was classified according to the Global Initiative for Asthma criteria. Subjects were grouped according to exposure type into 4 groups: smokers, household pollution, dual-exposure and no-exposure. Chi square, Mann–Whitney, and Kruskal–Wallis tests were used for comparisons between groups.

Results

Out of 996 included individuals, 78 (7.8%) were exposed to cigarette smoking alone, 358 (35.9%) to household pollution alone, 155 (15.6%) to the two exposures combined and 405 (40.7%) were not exposed. Compared to unexposed individuals, exposure to household pollution resulted in poorer asthma control, higher proportion of severe asthma, and worse indicators of lung function. The double-exposed individuals were worse off in all the evaluated parameters, and they were significantly worse than subjects with single exposure to household air pollution in relation to asthma severity and lung function. These subjects were predominantly females, older, with longer residence time in rural areas, lower income and lower schooling levels. Multivariate analysis showed that exposure to household pollution and double exposure were predictive factors associated with lack of control and increased severity of asthma.

Conclusions

Exposure to household pollution is associated with poorer control, greater severity, and poorer pulmonary function; double-exposed individuals have a greater risk of severe asthma and decreased lung function than those exposed only to household pollution.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RLo4pX

Re: Investigating sudden hearing loss in adults - The BMJ

Re: Investigating sudden hearing loss in adults  The BMJ

Dear Mr Fishman and Dr Cullen,. Thank you for writing this exhaustive article on sudden hearing loss which will be a useful guide to primary care, emergency ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EmAX74

Re: Investigating sudden hearing loss in adults - The BMJ

Re: Investigating sudden hearing loss in adults  The BMJ

Dear Mr Fishman and Dr Cullen,. Thank you for writing this exhaustive article on sudden hearing loss which will be a useful guide to primary care, emergency ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EmAX74

Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 - The Lancet

Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017  The Lancet

Assessments of age-specific mortality and life expectancy have been done by the UN Population Division, Department of Economics and Social Affairs (UNPOP) ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EnEdPt

Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 - The Lancet

Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017  The Lancet

Assessments of age-specific mortality and life expectancy have been done by the UN Population Division, Department of Economics and Social Affairs (UNPOP) ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EnEdPt

Here's Why Exelixis Stock Jumped 46.4% in November - The Motley Fool

?url=https%3A%2F%2Fg.foolcdn.com%2Fedito

Here's Why Exelixis Stock Jumped 46.4% in November  The Motley Fool

A third-quarter earnings surprise and a European approval gave the stock some lift.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Ec0JKk

Here's Why Exelixis Stock Jumped 46.4% in November - The Motley Fool

?url=https%3A%2F%2Fg.foolcdn.com%2Fedito

Here's Why Exelixis Stock Jumped 46.4% in November  The Motley Fool

A third-quarter earnings surprise and a European approval gave the stock some lift.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Ec0JKk

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines - UroToday

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines  UroToday

Affordability of recently licensed cancer medicines, use of English, French, and Australian health technology assessments (HTAs) to analyze all new cancer ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2C1Cm0x

Response Genetics (OTCMKTS:RGDXQ) and IDEXX Laboratories (IDXX) Financial Analysis - PressOracle

generic-stocks.jpg

Response Genetics (OTCMKTS:RGDXQ) and IDEXX Laboratories (IDXX) Financial Analysis  PressOracle

Response Genetics (OTCMKTS:RGDXQ) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the better stock? We will compare ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2LaLtPm

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines - UroToday

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines  UroToday

Affordability of recently licensed cancer medicines, use of English, French, and Australian health technology assessments (HTAs) to analyze all new cancer ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2C1Cm0x

Response Genetics (OTCMKTS:RGDXQ) and IDEXX Laboratories (IDXX) Financial Analysis - PressOracle

generic-stocks.jpg

Response Genetics (OTCMKTS:RGDXQ) and IDEXX Laboratories (IDXX) Financial Analysis  PressOracle

Response Genetics (OTCMKTS:RGDXQ) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the better stock? We will compare ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2LaLtPm

Interpace Diagnostics Group (IDXG) Received a $4.00 Target Price by Maxim Group Analysts - BharataPress

Interpace Diagnostics Group (IDXG) Received a $4.00 Target Price by Maxim Group Analysts  BharataPress

Interpace Diagnostics Group (NASDAQ:IDXG) has been given a $4.00 price target by research analysts at Maxim Group in a research note issued on ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L6QEjd

Interpace Diagnostics Group (IDXG) Received a $4.00 Target Price by Maxim Group Analysts - BharataPress

Interpace Diagnostics Group (IDXG) Received a $4.00 Target Price by Maxim Group Analysts  BharataPress

Interpace Diagnostics Group (NASDAQ:IDXG) has been given a $4.00 price target by research analysts at Maxim Group in a research note issued on ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L6QEjd

GMC’s cancer OPD sees 280 cases since starting in Sept-end - Times of India

GMC's cancer OPD sees 280 cases since starting in Sept-end  Times of India

Panaji: As many as 280 patients have registered at the cancer out-patient department (OPD) at Goa Medical College, Bambolim, since it started in the l.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2SANBlN

Insurer Faces $25.5m Payout After Denial of Proton Therapy - Medscape

Insurer Faces $25.5m Payout After Denial of Proton Therapy  Medscape

Health insurer Aetna denied proton therapy because it was 'experimental.' This jury verdict raises the possibility that other denial-of-care suits will follow.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2zfrk5O

GMC’s cancer OPD sees 280 cases since starting in Sept-end - Times of India

GMC's cancer OPD sees 280 cases since starting in Sept-end  Times of India

Panaji: As many as 280 patients have registered at the cancer out-patient department (OPD) at Goa Medical College, Bambolim, since it started in the l.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2SANBlN

Insurer Faces $25.5m Payout After Denial of Proton Therapy - Medscape

Insurer Faces $25.5m Payout After Denial of Proton Therapy  Medscape

Health insurer Aetna denied proton therapy because it was 'experimental.' This jury verdict raises the possibility that other denial-of-care suits will follow.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2zfrk5O

Boozing habits are bad enough to choke on - Hong Kong Standard

50026705contentPhoto1.jpg

Boozing habits are bad enough to choke on  Hong Kong Standard

More than a third of people in the SAR binge drink, according to a survey of 1,119 people by the Hong Kong Anti-Cancer Society. About 69 percent started ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2PsG3zr

Head And Neck Cancer Treatment Market 2017 – 2021: Analysis, Size, Share, Trends, Growth, Industry Report - The Dosdigitos

Image_3.png

Head And Neck Cancer Treatment Market 2017 – 2021: Analysis, Size, Share, Trends, Growth, Industry Report  The Dosdigitos

Head And Neck Cancer Treatment Market is analysed on the basis of: Business segments, Organizational developments, Geographical focus, Segment focus, ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2KF7lBZ

Boozing habits are bad enough to choke on - Hong Kong Standard

50026705contentPhoto1.jpg

Boozing habits are bad enough to choke on  Hong Kong Standard

More than a third of people in the SAR binge drink, according to a survey of 1,119 people by the Hong Kong Anti-Cancer Society. About 69 percent started ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2PsG3zr

Head And Neck Cancer Treatment Market 2017 – 2021: Analysis, Size, Share, Trends, Growth, Industry Report - The Dosdigitos

Image_3.png

Head And Neck Cancer Treatment Market 2017 – 2021: Analysis, Size, Share, Trends, Growth, Industry Report  The Dosdigitos

Head And Neck Cancer Treatment Market is analysed on the basis of: Business segments, Organizational developments, Geographical focus, Segment focus, ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2KF7lBZ

[Classification and pathophysiology of angioedema].

CONCLUSIONS: In most cases, mast cell mediator-induced and bradykinin-mediated forms of angioedema are readily classified clinically and/or by laboratory tests. In very rare cases, however, the cause and mediators of angioedema remain unknown. PMID: 30506093 [PubMed - as supplied by publisher] (Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RGJMvk

[Classification and pathophysiology of angioedema].

CONCLUSIONS: In most cases, mast cell mediator-induced and bradykinin-mediated forms of angioedema are readily classified clinically and/or by laboratory tests. In very rare cases, however, the cause and mediators of angioedema remain unknown. PMID: 30506093 [PubMed - as supplied by publisher] (Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RGJMvk

Imfinzi looks flimsy in AstraZeneca's Phase III head and neck cancer study - MedCity News

GettyImages-180820297-600x436.jpg

Imfinzi looks flimsy in AstraZeneca's Phase III head and neck cancer study  MedCity News

Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after progression on ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2UwqJWg

Imfinzi looks flimsy in AstraZeneca's Phase III head and neck cancer study - MedCity News

GettyImages-180820297-600x436.jpg

Imfinzi looks flimsy in AstraZeneca's Phase III head and neck cancer study  MedCity News

Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after progression on ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2UwqJWg

Oberweis Asset Management Increased Its New Jersey Res Corp. (NJR) Holding; Veracyte (VCYT)'s Sentiment Is 4.11 - The FinExaminer

VCYT.png

Oberweis Asset Management Increased Its New Jersey Res Corp. (NJR) Holding; Veracyte (VCYT)'s Sentiment Is 4.11  The FinExaminer

Oberweis Asset Management Inc increased New Jersey Res Corp. (NJR) stake by 78.17% reported in 2018Q2 SEC filing. Oberweis Asset Management Inc ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2C0MFSn

Oberweis Asset Management Increased Its New Jersey Res Corp. (NJR) Holding; Veracyte (VCYT)'s Sentiment Is 4.11 - The FinExaminer

VCYT.png

Oberweis Asset Management Increased Its New Jersey Res Corp. (NJR) Holding; Veracyte (VCYT)'s Sentiment Is 4.11  The FinExaminer

Oberweis Asset Management Inc increased New Jersey Res Corp. (NJR) stake by 78.17% reported in 2018Q2 SEC filing. Oberweis Asset Management Inc ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2C0MFSn

Essentia Health offers way to quit smoking for better health - The Lake Country Echo

Essentia Health offers way to quit smoking for better health  The Lake Country Echo

Thursday, Nov. 15, is the American Cancer Society's Great American Smokeout and Essentia Health wants to help smokers quit for good for better health.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2B5d3Zx

Essentia Health offers way to quit smoking for better health - The Lake Country Echo

Essentia Health offers way to quit smoking for better health  The Lake Country Echo

Thursday, Nov. 15, is the American Cancer Society's Great American Smokeout and Essentia Health wants to help smokers quit for good for better health.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2B5d3Zx

Re: Overdiagnosis and industry influence: how cow ’s milk protein allergy is extending the reach of infant formula manufacturers

(Source: BMJ Comments)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2zQdXsZ

Re: Overdiagnosis and industry influence: how cow ’s milk protein allergy is extending the reach of infant formula manufacturers

(Source: BMJ Comments)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2zQdXsZ

This river is too toxic to touch, and people live right next to it - The Desert Sun

This river is too toxic to touch, and people live right next to it  The Desert Sun

The New River is filled with sewage and toxic pollution. Despite more than $90 million spent, the Mexican and U.S. governments have failed to clean it up.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2BTnukN

This river is too toxic to touch, and people live right next to it - The Desert Sun

This river is too toxic to touch, and people live right next to it  The Desert Sun

The New River is filled with sewage and toxic pollution. Despite more than $90 million spent, the Mexican and U.S. governments have failed to clean it up.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2BTnukN

Long-term efficacy and dose-finding trial of Japanese cedar pollen SLIT tablet

ConclusionThe optimal dose of the JC pollen SLIT tablet was 5,000 JAU, with good efficacy and safety over a 3-year treatment period. This sustained effect was dependent on treatment duration. (Source: The Journal of Allergy and Clinical Immunology: In Practice)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RObmqA

Health utility scores of atopic dermatitis in US adults

ConclusionModerate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research. (Source: The Journal of Allergy and Clinical Immunology: In Practice)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RMMSy7

Seasonal Viral Influenza Among Persons with Primary Antibody Immunodeficiency

Publication date: Available online 8 December 2018Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Mark Ballow, Tiffany Henderson, Christopher Scalchunes, R. Michael Blaese (Source: The Journal of Allergy and Clinical Immunology: In Practice)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Qp5hEv

Long-term efficacy and dose-finding trial of Japanese cedar pollen SLIT tablet

ConclusionThe optimal dose of the JC pollen SLIT tablet was 5,000 JAU, with good efficacy and safety over a 3-year treatment period. This sustained effect was dependent on treatment duration. (Source: The Journal of Allergy and Clinical Immunology: In Practice)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RObmqA

Health utility scores of atopic dermatitis in US adults

ConclusionModerate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research. (Source: The Journal of Allergy and Clinical Immunology: In Practice)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RMMSy7

Seasonal Viral Influenza Among Persons with Primary Antibody Immunodeficiency

Publication date: Available online 8 December 2018Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Mark Ballow, Tiffany Henderson, Christopher Scalchunes, R. Michael Blaese (Source: The Journal of Allergy and Clinical Immunology: In Practice)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Qp5hEv

Independent Research Analysts Give Merck KGaA (FRA:MRK) a €100.00 Price Target - Fairfield Current

merck-kgaa-logo.JPG

Independent Research Analysts Give Merck KGaA (FRA:MRK) a €100.00 Price Target  Fairfield Current

Independent Research set a €100.00 ($116.28) price objective on Merck KGaA (FRA:MRK) in a research report report published on Thursday, November 15th.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2SCpPWt

Moon Fahel Finishes Fifth Marathon - Cancer Survivors and Running - Runner's World

Moon Fahel Finishes Fifth Marathon - Cancer Survivors and Running  Runner's World

Moon Fahel from San Antonio, Texas, had just gotten home from a martial arts class that he's been taking for the last 15 years when he answered the phone call ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2QJZPeD

Independent Research Analysts Give Merck KGaA (FRA:MRK) a €100.00 Price Target - Fairfield Current

merck-kgaa-logo.JPG

Independent Research Analysts Give Merck KGaA (FRA:MRK) a €100.00 Price Target  Fairfield Current

Independent Research set a €100.00 ($116.28) price objective on Merck KGaA (FRA:MRK) in a research report report published on Thursday, November 15th.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2SCpPWt

Moon Fahel Finishes Fifth Marathon - Cancer Survivors and Running - Runner's World

Moon Fahel Finishes Fifth Marathon - Cancer Survivors and Running  Runner's World

Moon Fahel from San Antonio, Texas, had just gotten home from a martial arts class that he's been taking for the last 15 years when he answered the phone call ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2QJZPeD

Nasal function and CPAP compliance

Publication date: Available online 8 December 2018

Source: Auris Nasus Larynx

Author(s): Akiko Inoue, Shintaro Chiba, Kentaro Matsuura, Hiroshi Osafune, Robson Capasso, Kota Wada

Abstract
Objective

Continuous positive airway pressure (CPAP) is the mainstay therapy for patients with obstructive sleep apnea (OSA) however compliance with CPAP is variable. Nasal ailments, such as nasal congestion are frequently mentioned as a cause for CPAP non-compliance, and potentially could be addressed prior to CPAP initiation, however, no specific criteria or recommendations for the evaluation and management of these patients exist. The aim of this retrospective study is to evaluate the effects of nasal anatomic features and disease on adherence to CPAP therapy for patients with OSA and determine the indications for pre-CPAP nasal treatment by using data obtained at clinical examination.

Methods

In total, 711 adult patients with initial diagnosis of OSA and an apnea–hypopnea index of ≥20 who were amenable to CPAP were included. We analyzed nasal parameters, past history of nasal disease, subjective symptoms, and disease severity in addition to whether CPAP therapy had been initiated, rate of CPAP therapy use (initial and 1 year), treatment continuation rate at 2 months and 1 year, and nasal treatments for all patients.

Results

CPAP therapy was initiated in 543 of 711 patients. Nasal resistance was significantly higher in patients who discontinued therapy soon after CPAP initiation. Nasal disease and nasal parameters were not found to be predictors of treatment adherence at 1 year.

Allergic rhinitis, moderate to severe nasal congestion at bedtime, slight or extensive sinus opacification, and a high nasal septum deviation score were found to be independent predictors of nasal treatment, while strong awareness of nasal congestion, a past history of sinusitis, and a total nasal resistance (supine position) of ≥0.35 Pa/cm3/s were independent predictors of surgical treatment.

Conclusion

Long-term CPAP therapy adherence in patients with OSA can be predicted from initial CPAP adherence. Nasal disease and nasal parameters are important factors for early CPAP therapy discontinuation and should be adequately treated before therapy initiation to ensure long-term adherence. Indications for pre-CPAP nasal treatment and nasal surgery for patients with OSA can be predicted from the data obtained at the first examination, and these patients should be treated differently from those without OSA.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2rux2wi

Nasal function and CPAP compliance

Publication date: Available online 8 December 2018

Source: Auris Nasus Larynx

Author(s): Akiko Inoue, Shintaro Chiba, Kentaro Matsuura, Hiroshi Osafune, Robson Capasso, Kota Wada

Abstract
Objective

Continuous positive airway pressure (CPAP) is the mainstay therapy for patients with obstructive sleep apnea (OSA) however compliance with CPAP is variable. Nasal ailments, such as nasal congestion are frequently mentioned as a cause for CPAP non-compliance, and potentially could be addressed prior to CPAP initiation, however, no specific criteria or recommendations for the evaluation and management of these patients exist. The aim of this retrospective study is to evaluate the effects of nasal anatomic features and disease on adherence to CPAP therapy for patients with OSA and determine the indications for pre-CPAP nasal treatment by using data obtained at clinical examination.

Methods

In total, 711 adult patients with initial diagnosis of OSA and an apnea–hypopnea index of ≥20 who were amenable to CPAP were included. We analyzed nasal parameters, past history of nasal disease, subjective symptoms, and disease severity in addition to whether CPAP therapy had been initiated, rate of CPAP therapy use (initial and 1 year), treatment continuation rate at 2 months and 1 year, and nasal treatments for all patients.

Results

CPAP therapy was initiated in 543 of 711 patients. Nasal resistance was significantly higher in patients who discontinued therapy soon after CPAP initiation. Nasal disease and nasal parameters were not found to be predictors of treatment adherence at 1 year.

Allergic rhinitis, moderate to severe nasal congestion at bedtime, slight or extensive sinus opacification, and a high nasal septum deviation score were found to be independent predictors of nasal treatment, while strong awareness of nasal congestion, a past history of sinusitis, and a total nasal resistance (supine position) of ≥0.35 Pa/cm3/s were independent predictors of surgical treatment.

Conclusion

Long-term CPAP therapy adherence in patients with OSA can be predicted from initial CPAP adherence. Nasal disease and nasal parameters are important factors for early CPAP therapy discontinuation and should be adequately treated before therapy initiation to ensure long-term adherence. Indications for pre-CPAP nasal treatment and nasal surgery for patients with OSA can be predicted from the data obtained at the first examination, and these patients should be treated differently from those without OSA.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2rux2wi

What exactly is a thyroid disorder? 20 things experts want us all to know about this vital gland - Irish Examiner

ee8a9725-b7cd-4e3a-8a30-131bf93bdf38.jpg

What exactly is a thyroid disorder? 20 things experts want us all to know about this vital gland  Irish Examiner

Thyroid disorders are believed to affect around one in 20 people in the UK, yet because the symptoms – such as weight changes, depression and fatigue – can ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2BDShSk

What exactly is a thyroid disorder? 20 things experts want us all to know about this vital gland - Irish Examiner

ee8a9725-b7cd-4e3a-8a30-131bf93bdf38.jpg

What exactly is a thyroid disorder? 20 things experts want us all to know about this vital gland  Irish Examiner

Thyroid disorders are believed to affect around one in 20 people in the UK, yet because the symptoms – such as weight changes, depression and fatigue – can ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2BDShSk

Measurement of radioxenon and radioargon in air from soil with elevated uranium concentration

Publication date: February 2019

Source: Journal of Environmental Radioactivity, Volume 197

Author(s): J. Kastlander, M. Aldener, T. Fritioff, L. Raghoo, R. Purtschert

Abstract

Among the most important indicators for an underground nuclear explosion are the radioactive xenon isotopes 131mXe, 133Xe, 133mXe and 135Xe and the radioactive argon isotope 37Ar. In order to evaluate a detection of these nuclides in the context of a nuclear test verification regime it is crucial to have knowledge about expected background concentrations. Sub soil gas sampling was carried out on the oil shale ash waste pile in Kvarntorp, Sweden, a location with known elevated uranium content where 133Xe and 37Ar were detected in concentrations up to 120 mBq/m3 and 40 mBq/m3 respectively. These data provides one of the first times when xenon and argon were both detected in the same sub soil gas. This, and the correlations between the radionuclides, the sub soil gas contents (i.e. CO2, O2, and radon) and uranium concentration in the pile, provide very interesting information regarding the natural background and the xenon concentration levels and can most likely be used as an upper limit on what to be expected naturally occurring.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Ecn0rw

Measurement of radioxenon and radioargon in air from soil with elevated uranium concentration

Publication date: February 2019

Source: Journal of Environmental Radioactivity, Volume 197

Author(s): J. Kastlander, M. Aldener, T. Fritioff, L. Raghoo, R. Purtschert

Abstract

Among the most important indicators for an underground nuclear explosion are the radioactive xenon isotopes 131mXe, 133Xe, 133mXe and 135Xe and the radioactive argon isotope 37Ar. In order to evaluate a detection of these nuclides in the context of a nuclear test verification regime it is crucial to have knowledge about expected background concentrations. Sub soil gas sampling was carried out on the oil shale ash waste pile in Kvarntorp, Sweden, a location with known elevated uranium content where 133Xe and 37Ar were detected in concentrations up to 120 mBq/m3 and 40 mBq/m3 respectively. These data provides one of the first times when xenon and argon were both detected in the same sub soil gas. This, and the correlations between the radionuclides, the sub soil gas contents (i.e. CO2, O2, and radon) and uranium concentration in the pile, provide very interesting information regarding the natural background and the xenon concentration levels and can most likely be used as an upper limit on what to be expected naturally occurring.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Ecn0rw

University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years - Imaging Technology News

University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years  Imaging Technology News

Iodine-131 is critical radioisotope for diagnoses and treatment of thyroid cancer and hyperthyroidism.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2B4zJdv

Exelixis, Inc. (EXEL) EVP Jeffrey Hessekiel Sells 11,759 Shares - Fairfield Current

exelixis-inc-logo.gif

Exelixis, Inc. (EXEL) EVP Jeffrey Hessekiel Sells 11,759 Shares  Fairfield Current

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 11759 shares of the business's stock in a transaction on Wednesday, November 28th. The shares ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Envltf

University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years - Imaging Technology News

University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years  Imaging Technology News

Iodine-131 is critical radioisotope for diagnoses and treatment of thyroid cancer and hyperthyroidism.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2B4zJdv

Exelixis, Inc. (EXEL) EVP Jeffrey Hessekiel Sells 11,759 Shares - Fairfield Current

exelixis-inc-logo.gif

Exelixis, Inc. (EXEL) EVP Jeffrey Hessekiel Sells 11,759 Shares  Fairfield Current

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 11759 shares of the business's stock in a transaction on Wednesday, November 28th. The shares ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Envltf

ALLERGY RELIEF-D (Cetirizine Hydrochloride And Pseudoephedrine Hydrochloride) Tablet, Film Coated, Extended Release [CHAIN DRUG CONSORTIUM,LLC]

Updated Date: Dec 7, 2018 EST (Source: DailyMed Drug Label Updates)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EiHmjq

ALL DAY ALLERGY RELIEF D (Cetirizine Hcl, Pseudoephedrine Hcl) Tablet, Extended Release [H E B]

Updated Date: Dec 7, 2018 EST (Source: DailyMed Drug Label Updates)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EbaaJK

ALL DAY ALLERGY RELIEF D (Cetirizine Hcl, Pseudoephedrine Hcl) Tablet, Extended Release [H E B]

Updated Date: Dec 7, 2018 EST (Source: DailyMed Drug Label Updates)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EbaaJK

ALLERGY RELIEF-D (Cetirizine Hydrochloride And Pseudoephedrine Hydrochloride) Tablet, Film Coated, Extended Release [CHAIN DRUG CONSORTIUM,LLC]

Updated Date: Dec 7, 2018 EST (Source: DailyMed Drug Label Updates)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EiHmjq

Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma - Journal of Nuclear Medicine

Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma  Journal of Nuclear Medicine

+ Author Affiliations. 1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania. 2Department of Radiology, University of Pittsburgh, ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2rsbRLi

Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma - Journal of Nuclear Medicine

Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma  Journal of Nuclear Medicine

+ Author Affiliations. 1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania. 2Department of Radiology, University of Pittsburgh, ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2rsbRLi

Reduced Radiation Dose with Model Based Iterative Reconstruction Coronary Artery Calcium Scoring

Publication date: Available online 8 December 2018

Source: European Journal of Radiology

Author(s): Andrew D. Choi, Eric S. Leifer, Jeannie Yu, Tanuka Datta, Kathie Bronson, Shirley Rollison, John Schuzer, Chloe Steveson, Sujata M. Shanbhag, Marcus Y. Chen

Abstract

Assessing coronary artery calcium (CAC) is a valuable tool for individualizing cardiac risk assessment. In CAC scanning, this technical report assesses the use of a true model-based iterative reconstruction algorithm using forward projected model-based iterative reconstruction ("FIRST") and assess whether FIRST allows for reduced radiation dose CAC scanning on 320-detector row computed tomography (320-CT). Here, 100 consecutive patients prospectively underwent reduced and standard dose scans. For the patients (59 ± 9 years, 61% male) stratified by Agatston categories 0, 1-10, 11-100, 101-400,> 400, agreement between reduced dose with FIRST versus standard dose with FBP was excellent at 81% (95% CI: 73-88%) with kappa 0.74 (95% CI: 0.64–0.85). Median radiation exposure was 75% lower for reduced (0.35 mSv) versus standard dose (1.37 mSv) scans. In conclusion, agreement was excellent for reduced dose with FIRST and standard dose with FBP in 320-detector row CT CAC imaging in well-established categories of cardiovascular risk. These methods make it possible to reduce radiation exposure by 75%.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EbnaiM

Reduced Radiation Dose with Model Based Iterative Reconstruction Coronary Artery Calcium Scoring

Publication date: Available online 8 December 2018

Source: European Journal of Radiology

Author(s): Andrew D. Choi, Eric S. Leifer, Jeannie Yu, Tanuka Datta, Kathie Bronson, Shirley Rollison, John Schuzer, Chloe Steveson, Sujata M. Shanbhag, Marcus Y. Chen

Abstract

Assessing coronary artery calcium (CAC) is a valuable tool for individualizing cardiac risk assessment. In CAC scanning, this technical report assesses the use of a true model-based iterative reconstruction algorithm using forward projected model-based iterative reconstruction ("FIRST") and assess whether FIRST allows for reduced radiation dose CAC scanning on 320-detector row computed tomography (320-CT). Here, 100 consecutive patients prospectively underwent reduced and standard dose scans. For the patients (59 ± 9 years, 61% male) stratified by Agatston categories 0, 1-10, 11-100, 101-400,> 400, agreement between reduced dose with FIRST versus standard dose with FBP was excellent at 81% (95% CI: 73-88%) with kappa 0.74 (95% CI: 0.64–0.85). Median radiation exposure was 75% lower for reduced (0.35 mSv) versus standard dose (1.37 mSv) scans. In conclusion, agreement was excellent for reduced dose with FIRST and standard dose with FBP in 320-detector row CT CAC imaging in well-established categories of cardiovascular risk. These methods make it possible to reduce radiation exposure by 75%.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EbnaiM

Diffusely decreased liver attenuation on post-mortem computed tomography: comparison with ante-mortem computed tomography and autopsy findings

Publication date: Available online 8 December 2018

Source: Journal of Forensic Radiology and Imaging

Author(s): Masanori Ishida, Wataru Gonoi, Go Shirota, Hidemi Okuma, Sho Yamazawa, Munetoshi Hinata, Akimasa Hayashi, Masashi Fukayama, Osamu Abe

Abstract

We present two cases of diffusely decreased liver attenuation on post-mortem computed tomography (CT) which is lower than that on ante-mortem CT. Cases include a 37-year-old female whose cause of death was related to myelodysplastic syndrome (Case #1) and an 88-year-old female whose cause of death was related to malignant lymphoma (Case #2). We compared post-mortem CT (PMCT) liver attenuations with those on ante-mortem CT (AMCT). For Case #1, average AMCT values of the right/left liver were 46.1/50.0 Hounsfield Units (HU) 2 days ante-mortem and PMCT values of the right/left liver were 33.9/38.4 HU 3 hours post-mortem. For Case #2, average AMCT values were 61.4/54.9 HU 5 days ante-mortem and PMCT values of the right/left liver were 38.2/40.6 HU 2 hours post-mortem. In both Case # 1 and #2, decreased liver attenuations were found on PMCT. Further, autopsy revealed diffuse hepatocellular hemorrhage, deficits, and necrosis in Case #1, and liver infiltration of lymphoma in Case #2. These pathological findings were considered to be related to diffusely decreased liver attenuation on PMCT in conjunction with remarkable deterioration of hepatobiliary function before death. The observed decreases in liver attenuation on PMCT may be attributed mainly to hepatic pathological changes just prior to death. PMCT liver attenuation does not necessarily reflect the ante-mortem state some time before death, and it is therefore necessary to be careful when presuming the ante-mortem hepatic pathological conditions from only PMCT. This attenuation change should be taken into account during PMCT interpretation.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2G7MAjW

Diffusely decreased liver attenuation on post-mortem computed tomography: comparison with ante-mortem computed tomography and autopsy findings

Publication date: Available online 8 December 2018

Source: Journal of Forensic Radiology and Imaging

Author(s): Masanori Ishida, Wataru Gonoi, Go Shirota, Hidemi Okuma, Sho Yamazawa, Munetoshi Hinata, Akimasa Hayashi, Masashi Fukayama, Osamu Abe

Abstract

We present two cases of diffusely decreased liver attenuation on post-mortem computed tomography (CT) which is lower than that on ante-mortem CT. Cases include a 37-year-old female whose cause of death was related to myelodysplastic syndrome (Case #1) and an 88-year-old female whose cause of death was related to malignant lymphoma (Case #2). We compared post-mortem CT (PMCT) liver attenuations with those on ante-mortem CT (AMCT). For Case #1, average AMCT values of the right/left liver were 46.1/50.0 Hounsfield Units (HU) 2 days ante-mortem and PMCT values of the right/left liver were 33.9/38.4 HU 3 hours post-mortem. For Case #2, average AMCT values were 61.4/54.9 HU 5 days ante-mortem and PMCT values of the right/left liver were 38.2/40.6 HU 2 hours post-mortem. In both Case # 1 and #2, decreased liver attenuations were found on PMCT. Further, autopsy revealed diffuse hepatocellular hemorrhage, deficits, and necrosis in Case #1, and liver infiltration of lymphoma in Case #2. These pathological findings were considered to be related to diffusely decreased liver attenuation on PMCT in conjunction with remarkable deterioration of hepatobiliary function before death. The observed decreases in liver attenuation on PMCT may be attributed mainly to hepatic pathological changes just prior to death. PMCT liver attenuation does not necessarily reflect the ante-mortem state some time before death, and it is therefore necessary to be careful when presuming the ante-mortem hepatic pathological conditions from only PMCT. This attenuation change should be taken into account during PMCT interpretation.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2G7MAjW

Long-term efficacy and dose-finding trial of Japanese cedar pollen SLIT tablet

Publication date: Available online 8 December 2018

Source: The Journal of Allergy and Clinical Immunology: In Practice

Author(s): Minoru Gotoh, Syuji Yonekura, Toru Imai, Shinya Kaneko, Eiji Horikawa, Akiyoshi Konno, Yoshitaka Okamoto, Kimihiro Okubo

Abstract
Background

Japanese cedar (JC) pollinosis is a common allergic rhinitis in Japan. The JC pollen SLIT tablet was developed using the highest concentration of JC pollen extract.

Objective

This was a randomized, double-blind, placebo-controlled phase II/III trial to investigate the optimal dose of the JC pollen SLIT tablet and examine long-term efficacy and safety for 3 years with the selected dose, and 2-year follow-up.

Methods

A total 1,042 patients with JC pollinosis (aged 5–64 years) were equally randomized into four groups and received daily treatment with 2,000, 5,000, or 10,000 Japanese allergy unit (JAU) or placebo. The primary endpoint was the total nasal symptom and medication score (TNSMS) during the peak symptom period in the first season. Key secondary endpoints were TNSMS for the JC pollen dispersion season and total nasal and ocular symptom and medication score (TNOSMS) for the peak symptom period and JC pollen dispersion season.

Results

For the primary endpoint, absolute reductions and relative mean reductions in TNSMS compared with placebo were 1.50 and 21.4%, 2.24 and 32.1%, and 2.18 and 31.2% for 2,000, 5,000, and 10,000 JAU, respectively (P < .001 in all groups). For all key secondary endpoints, efficacy was confirmed for all doses (P < .001 in all groups). The treatment was well tolerated. Long-term efficacy of 5,000 JAU was shown over the 3 years.

Conclusion

The optimal dose of the JC pollen SLIT tablet was 5,000 JAU, with good efficacy and safety over a 3-year treatment period. This sustained effect was dependent on treatment duration.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L67bUz

Seasonal Viral Influenza Among Persons with Primary Antibody Immunodeficiency

Publication date: Available online 8 December 2018

Source: The Journal of Allergy and Clinical Immunology: In Practice

Author(s): Mark Ballow, Tiffany Henderson, Christopher Scalchunes, R. Michael Blaese



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2BYEXIe

Health utility scores of atopic dermatitis in US adults

Publication date: Available online 8 December 2018

Source: The Journal of Allergy and Clinical Immunology: In Practice

Author(s): Jonathan I. Silverberg, Joel M. Gelfand, David J. Margolis, Mark Boguniewicz, Luz Fonacier, Mitchell H. Grayson, Peck Y. Ong, Zelma Chiesa Fuxench, Eric L. Simpson

Background

The impact of atopic dermatitis (AD) on health related quality of life and health utility in the United States adult population is not well-established.

Objectives

To determine the health utilities and quality of life adjusted years (QALYs) lost in adults with vs. without AD among the US population.

Methods

A cross-sectional, population-based study of 3,495 adults was performed. AD was determined using modified UK Diagnostic Criteria for AD. AD severity was assessed using self-reported global AD severity, Patient-Oriented Eczema Measure (POEM), Patient-Oriented Scoring AD (PO-SCORAD), PO-SCORAD-itch and sleep. SF-6D health utility scores and total QALY loss were assessed.

Results

The mean [95% confidence interval] SF-6D score was lower in adults with AD compared to healthy adults (0.69 [0.68-0.70] vs. 0.79 [0.77-0.79]). In particular, moderate-severe AD (mean: 0.53-0.66) had similar or lower SF-6D scores than all other self-reported disorders examined, except autoimmune disorders. Adults with AD and atopic comorbidities had significantly lower SF-6D scores compared to those without atopic comorbidities. Among the 7 disorders examined, AD was associated with higher total QALY loss than autoimmune disorders, diabetes, food allergy, and heart disease in both males and females. The largest QALY loss was for moderate AD in females and mild AD in males.

Conclusion

Moderate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L5ZXjw

Long-term efficacy and dose-finding trial of Japanese cedar pollen SLIT tablet

Publication date: Available online 8 December 2018

Source: The Journal of Allergy and Clinical Immunology: In Practice

Author(s): Minoru Gotoh, Syuji Yonekura, Toru Imai, Shinya Kaneko, Eiji Horikawa, Akiyoshi Konno, Yoshitaka Okamoto, Kimihiro Okubo

Abstract
Background

Japanese cedar (JC) pollinosis is a common allergic rhinitis in Japan. The JC pollen SLIT tablet was developed using the highest concentration of JC pollen extract.

Objective

This was a randomized, double-blind, placebo-controlled phase II/III trial to investigate the optimal dose of the JC pollen SLIT tablet and examine long-term efficacy and safety for 3 years with the selected dose, and 2-year follow-up.

Methods

A total 1,042 patients with JC pollinosis (aged 5–64 years) were equally randomized into four groups and received daily treatment with 2,000, 5,000, or 10,000 Japanese allergy unit (JAU) or placebo. The primary endpoint was the total nasal symptom and medication score (TNSMS) during the peak symptom period in the first season. Key secondary endpoints were TNSMS for the JC pollen dispersion season and total nasal and ocular symptom and medication score (TNOSMS) for the peak symptom period and JC pollen dispersion season.

Results

For the primary endpoint, absolute reductions and relative mean reductions in TNSMS compared with placebo were 1.50 and 21.4%, 2.24 and 32.1%, and 2.18 and 31.2% for 2,000, 5,000, and 10,000 JAU, respectively (P < .001 in all groups). For all key secondary endpoints, efficacy was confirmed for all doses (P < .001 in all groups). The treatment was well tolerated. Long-term efficacy of 5,000 JAU was shown over the 3 years.

Conclusion

The optimal dose of the JC pollen SLIT tablet was 5,000 JAU, with good efficacy and safety over a 3-year treatment period. This sustained effect was dependent on treatment duration.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L67bUz

Seasonal Viral Influenza Among Persons with Primary Antibody Immunodeficiency

Publication date: Available online 8 December 2018

Source: The Journal of Allergy and Clinical Immunology: In Practice

Author(s): Mark Ballow, Tiffany Henderson, Christopher Scalchunes, R. Michael Blaese



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2BYEXIe

Health utility scores of atopic dermatitis in US adults

Publication date: Available online 8 December 2018

Source: The Journal of Allergy and Clinical Immunology: In Practice

Author(s): Jonathan I. Silverberg, Joel M. Gelfand, David J. Margolis, Mark Boguniewicz, Luz Fonacier, Mitchell H. Grayson, Peck Y. Ong, Zelma Chiesa Fuxench, Eric L. Simpson

Background

The impact of atopic dermatitis (AD) on health related quality of life and health utility in the United States adult population is not well-established.

Objectives

To determine the health utilities and quality of life adjusted years (QALYs) lost in adults with vs. without AD among the US population.

Methods

A cross-sectional, population-based study of 3,495 adults was performed. AD was determined using modified UK Diagnostic Criteria for AD. AD severity was assessed using self-reported global AD severity, Patient-Oriented Eczema Measure (POEM), Patient-Oriented Scoring AD (PO-SCORAD), PO-SCORAD-itch and sleep. SF-6D health utility scores and total QALY loss were assessed.

Results

The mean [95% confidence interval] SF-6D score was lower in adults with AD compared to healthy adults (0.69 [0.68-0.70] vs. 0.79 [0.77-0.79]). In particular, moderate-severe AD (mean: 0.53-0.66) had similar or lower SF-6D scores than all other self-reported disorders examined, except autoimmune disorders. Adults with AD and atopic comorbidities had significantly lower SF-6D scores compared to those without atopic comorbidities. Among the 7 disorders examined, AD was associated with higher total QALY loss than autoimmune disorders, diabetes, food allergy, and heart disease in both males and females. The largest QALY loss was for moderate AD in females and mild AD in males.

Conclusion

Moderate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L5ZXjw

Managing Afib in Cancer Patients Taking BTK Inhibitors - Cancer Network

Managing Afib in Cancer Patients Taking BTK Inhibitors  Cancer Network

Cancer Network speaks with Dr. Leon Ptaszek about managing cancer patients who have atrial fibrillation and are being treated with BTK inhibitors.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2rlqgJd

ITL Pharma Receives United States Patent Protection for Carcinin® Using Halogenated Phenol Ethers for Diagnostics, Antioxidant Protection and Drug Delivery - GlobeNewswire

ITL Pharma Receives United States Patent Protection for Carcinin® Using Halogenated Phenol Ethers for Diagnostics, Antioxidant Protection and Drug Delivery  GlobeNewswire

KINGSPORT, Tenn., Nov. 26, 2018 (GLOBE NEWSWIRE) -- ITL Pharma, Inc. (ITL), a LIAS Company, today announced awarding of a United States Patent ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2TIS4EB

ITL Pharma Receives United States Patent Protection for Carcinin® Using Halogenated Phenol Ethers for Diagnostics, Antioxidant Protection and Drug Delivery - GlobeNewswire

ITL Pharma Receives United States Patent Protection for Carcinin® Using Halogenated Phenol Ethers for Diagnostics, Antioxidant Protection and Drug Delivery  GlobeNewswire

KINGSPORT, Tenn., Nov. 26, 2018 (GLOBE NEWSWIRE) -- ITL Pharma, Inc. (ITL), a LIAS Company, today announced awarding of a United States Patent ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2TIS4EB

Managing Afib in Cancer Patients Taking BTK Inhibitors - Cancer Network

Managing Afib in Cancer Patients Taking BTK Inhibitors  Cancer Network

Cancer Network speaks with Dr. Leon Ptaszek about managing cancer patients who have atrial fibrillation and are being treated with BTK inhibitors.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2rlqgJd

Thyroid Cancer Treatment Industry Findings - Top competitors, Market Size and Revenue, End User Applications - TokenQuire

Thyroid-Cancer-Treatment-111625.jpg

Thyroid Cancer Treatment Industry Findings - Top competitors, Market Size and Revenue, End User Applications  TokenQuire

The objective of Thyroid Cancer Treatment Market Industry report is to enlighten the users with the crucial aspects of Global Thyroid Cancer Treatment Market ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2zOFonf

Neural architecture supporting active emotion processing in children: A multivariate approach

Publication date: Available online 8 December 2018

Source: NeuroImage

Author(s): M. Catalina Camacho, Helmet T. Karim, Susan B. Perlman

Abstract
Background

Adaptive emotion processing is critical for nearly all aspects of social and emotional functioning. There are distinct developmental trajectories associated with improved emotion processing, with a protracted developmental course for negative or complex emotions. The specific changes in neural circuitry that underlie this development, however are still scarcely understood. We employed a multivariate approach in order to elucidate distinctions in complex, naturalistic emotion processing between childhood and adulthood.

Method

Twenty-one adults (M±SD age = 26.57 ± 5.08 years) and thirty children (age = 7.75 ± 1.80 years) completed a free-viewing movie task during BOLD fMRI scanning. This task was designed to assess naturalistic processing of movie clips portraying positive, negative, and neutral emotions. Multivariate support vector machines (SVM) were trained to classify age groups based on neural activation during the task.

Results

SVMs were able to successfully classify condition (positive, negative, and neutral) across all participants with high accuracy (61.44%). SVMs could successfully distinguish adults and children within each condition (ps < 0.05). Regions that informed the age group SVMs were associated with sensory and socio-emotional processing (inferior parietal lobule), emotion regulation (inferior frontal gyrus), and sensory regions of the temporal and occipital lobes.

Conclusions

These results point to distributed differences in activation between childhood and adulthood unique to each emotional condition. In the negative condition specifically, there is evidence for a shift in engagement from regions of sensory and socio-emotional integration to emotion regulation regions between children and adults. These results provide insight into circuitry contributing to maturation of emotional processing across development.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Uwn3Uq

Age-related differences in task-induced brain activation is not task specific: Multivariate pattern generalization between metacognition, cognition and perception

Publication date: Available online 8 December 2018

Source: NeuroImage

Author(s): Esther H.H. Keulers, María Björk Birkisdóttir, Luciana Falbo, Anique de Bruin, Peter L.J. Stiers

Abstract

Adolescence is associated with widespread maturation of brain structures and functional connectivity profiles that shift from local to more distributed and better integrated networks, which are active during a variety of cognitive tasks. Nevertheless, the approach to examine task-induced developmental brain changes is function-specific, leaving the question open whether functional maturation is specific to the particular cognitive demands of the task used, or generalizes across different tasks. In the present study we examine the hypothesis that functional brain maturation is driven by global changes in how the brain handles cognitive demands. Multivariate pattern classification analysis (MVPA) was used to examine whether age discriminative task-induced activation patterns generalize across a wide range of information processing levels. 25 young (13-years old) and 22 old (17-years old) adolescents performed three conceptually different tasks of metacognition, cognition and visual processing. MVPA applied within each task indicated that task-induced brain activation is consistent and reliably different between ages 13 and 17. These age-discriminative activation patterns proved to be common across the different tasks used, despite the differences in cognitive demands and brain structures engaged by each of the three tasks. MVP classifiers trained to detect age-discriminative patterns in brain activation during one task were significantly able to decode age from brain activation maps during execution of other tasks with accuracies between 63 and 75%. The results emphasize that age-specific characteristics of task-induced brain activation have to be understood at the level of brain-wide networks that show maturational changes in their organization and processing efficacy during adolescence.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2zQxBVN

Age-related differences in task-induced brain activation is not task specific: Multivariate pattern generalization between metacognition, cognition and perception

Publication date: Available online 8 December 2018

Source: NeuroImage

Author(s): Esther H.H. Keulers, María Björk Birkisdóttir, Luciana Falbo, Anique de Bruin, Peter L.J. Stiers

Abstract

Adolescence is associated with widespread maturation of brain structures and functional connectivity profiles that shift from local to more distributed and better integrated networks, which are active during a variety of cognitive tasks. Nevertheless, the approach to examine task-induced developmental brain changes is function-specific, leaving the question open whether functional maturation is specific to the particular cognitive demands of the task used, or generalizes across different tasks. In the present study we examine the hypothesis that functional brain maturation is driven by global changes in how the brain handles cognitive demands. Multivariate pattern classification analysis (MVPA) was used to examine whether age discriminative task-induced activation patterns generalize across a wide range of information processing levels. 25 young (13-years old) and 22 old (17-years old) adolescents performed three conceptually different tasks of metacognition, cognition and visual processing. MVPA applied within each task indicated that task-induced brain activation is consistent and reliably different between ages 13 and 17. These age-discriminative activation patterns proved to be common across the different tasks used, despite the differences in cognitive demands and brain structures engaged by each of the three tasks. MVP classifiers trained to detect age-discriminative patterns in brain activation during one task were significantly able to decode age from brain activation maps during execution of other tasks with accuracies between 63 and 75%. The results emphasize that age-specific characteristics of task-induced brain activation have to be understood at the level of brain-wide networks that show maturational changes in their organization and processing efficacy during adolescence.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2zQxBVN

Neural architecture supporting active emotion processing in children: A multivariate approach

Publication date: Available online 8 December 2018

Source: NeuroImage

Author(s): M. Catalina Camacho, Helmet T. Karim, Susan B. Perlman

Abstract
Background

Adaptive emotion processing is critical for nearly all aspects of social and emotional functioning. There are distinct developmental trajectories associated with improved emotion processing, with a protracted developmental course for negative or complex emotions. The specific changes in neural circuitry that underlie this development, however are still scarcely understood. We employed a multivariate approach in order to elucidate distinctions in complex, naturalistic emotion processing between childhood and adulthood.

Method

Twenty-one adults (M±SD age = 26.57 ± 5.08 years) and thirty children (age = 7.75 ± 1.80 years) completed a free-viewing movie task during BOLD fMRI scanning. This task was designed to assess naturalistic processing of movie clips portraying positive, negative, and neutral emotions. Multivariate support vector machines (SVM) were trained to classify age groups based on neural activation during the task.

Results

SVMs were able to successfully classify condition (positive, negative, and neutral) across all participants with high accuracy (61.44%). SVMs could successfully distinguish adults and children within each condition (ps < 0.05). Regions that informed the age group SVMs were associated with sensory and socio-emotional processing (inferior parietal lobule), emotion regulation (inferior frontal gyrus), and sensory regions of the temporal and occipital lobes.

Conclusions

These results point to distributed differences in activation between childhood and adulthood unique to each emotional condition. In the negative condition specifically, there is evidence for a shift in engagement from regions of sensory and socio-emotional integration to emotion regulation regions between children and adults. These results provide insight into circuitry contributing to maturation of emotional processing across development.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Uwn3Uq

Identification of novel allergic diathesis genes: are we closer to novel therapeutic targets?

Publication date: Available online 8 December 2018

Source: Journal of Allergy and Clinical Immunology

Author(s): Michelle Daya, Kathleen C. Barnes



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2E7StuS

Serious Asthma Events with Mometasone Furoate Plus Formoterol Compared With Mometasone Furoate

Publication date: Available online 8 December 2018

Source: Journal of Allergy and Clinical Immunology

Author(s): Cindy L.J. Weinstein, Nicholas Ryan, Tulin Shekar, Davis Gates, Stephen J. Lane, Ioana Agache, Robert A. Nathan, SPIRO Investigators

Abstract
Background

The safety of long-acting beta agonists added to inhaled corticosteroids for the treatment of persistent asthma has been controversial.

Objective

To determine whether administering formoterol in combination with mometasone furoate increases the risk of serious asthma outcomes compared to mometasone furoate alone.

Methods

We conducted a 26-week, randomized, double-blind trial in adolescent and adult patients (≥12 years) with persistent asthma in 35 countries with the primary objective of evaluating whether mometasone furoate-formoterol increases the risk of serious asthma outcomes (adjudicated hospitalization, intubation, or death) compared to mometasone furoate alone. The key efficacy endpoint was asthma exacerbation (composite of hospitalizations ≥24 h, emergency visits <24 h requiring systemic corticosteroid, or systemic corticosteroid for ≥3 consecutive days).

Results

Among 11,729 patients (mometasone furoate-formoterol, n=5868; mometasone furoate, n=5861), a total of 81 serious asthma outcomes, all asthma-related hospitalizations, were observed in 71 patients; 45 events from 39 patients on mometasone furoate-formoterol and 36 events from 32 patients on mometasone furoate. The hazard ratio for the first serious asthma outcome in the mometasone furoate-formoterol versus mometasone furoate group was 1.22 (95% CI: 0.76 to 1.94, p=0.411). Asthma exacerbation occurred in 1487 patients; 708 on mometasone furoate-formoterol and 779 on mometasone furoate. The hazard ratio for the first asthma exacerbation in the mometasone furoate-formoterol versus mometasone furoate group was 0.89 (95% CI: 0.80 to 0.98, p=0.021).

Conclusions

The addition of formoterol to mometasone maintenance therapy did not increase the risk of serious asthma-related events and reduced the risk of asthma exacerbation.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EouV5C

Identification of novel allergic diathesis genes: are we closer to novel therapeutic targets?

Publication date: Available online 8 December 2018

Source: Journal of Allergy and Clinical Immunology

Author(s): Michelle Daya, Kathleen C. Barnes



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2E7StuS

Serious Asthma Events with Mometasone Furoate Plus Formoterol Compared With Mometasone Furoate

Publication date: Available online 8 December 2018

Source: Journal of Allergy and Clinical Immunology

Author(s): Cindy L.J. Weinstein, Nicholas Ryan, Tulin Shekar, Davis Gates, Stephen J. Lane, Ioana Agache, Robert A. Nathan, SPIRO Investigators

Abstract
Background

The safety of long-acting beta agonists added to inhaled corticosteroids for the treatment of persistent asthma has been controversial.

Objective

To determine whether administering formoterol in combination with mometasone furoate increases the risk of serious asthma outcomes compared to mometasone furoate alone.

Methods

We conducted a 26-week, randomized, double-blind trial in adolescent and adult patients (≥12 years) with persistent asthma in 35 countries with the primary objective of evaluating whether mometasone furoate-formoterol increases the risk of serious asthma outcomes (adjudicated hospitalization, intubation, or death) compared to mometasone furoate alone. The key efficacy endpoint was asthma exacerbation (composite of hospitalizations ≥24 h, emergency visits <24 h requiring systemic corticosteroid, or systemic corticosteroid for ≥3 consecutive days).

Results

Among 11,729 patients (mometasone furoate-formoterol, n=5868; mometasone furoate, n=5861), a total of 81 serious asthma outcomes, all asthma-related hospitalizations, were observed in 71 patients; 45 events from 39 patients on mometasone furoate-formoterol and 36 events from 32 patients on mometasone furoate. The hazard ratio for the first serious asthma outcome in the mometasone furoate-formoterol versus mometasone furoate group was 1.22 (95% CI: 0.76 to 1.94, p=0.411). Asthma exacerbation occurred in 1487 patients; 708 on mometasone furoate-formoterol and 779 on mometasone furoate. The hazard ratio for the first asthma exacerbation in the mometasone furoate-formoterol versus mometasone furoate group was 0.89 (95% CI: 0.80 to 0.98, p=0.021).

Conclusions

The addition of formoterol to mometasone maintenance therapy did not increase the risk of serious asthma-related events and reduced the risk of asthma exacerbation.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EouV5C

Interpace Diagnostics Group Inc (IDXG) Receives Average Rating of “Buy” from Analysts - Fairfield Current

pdi-logo.jpg

Interpace Diagnostics Group Inc (IDXG) Receives Average Rating of "Buy" from Analysts  Fairfield Current

Shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) have been assigned an average rating of "Buy" from the seven ratings firms that are currently ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2G5lGJt

Contrasting Veracyte (VCYT) and Guardant Health (GH) - Fairfield Current

veracyte-logo.jpg

Contrasting Veracyte (VCYT) and Guardant Health (GH)  Fairfield Current

Veracyte (NASDAQ:VCYT) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the superior business? We will compare the two ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2QJXU9Q

Contrasting Veracyte (VCYT) and Guardant Health (GH) - Fairfield Current

veracyte-logo.jpg

Contrasting Veracyte (VCYT) and Guardant Health (GH)  Fairfield Current

Veracyte (NASDAQ:VCYT) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the superior business? We will compare the two ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2QJXU9Q

Interpace Diagnostics Group Inc (IDXG) Receives Average Rating of “Buy” from Analysts - Fairfield Current

pdi-logo.jpg

Interpace Diagnostics Group Inc (IDXG) Receives Average Rating of "Buy" from Analysts  Fairfield Current

Shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) have been assigned an average rating of "Buy" from the seven ratings firms that are currently ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2G5lGJt

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

Condition:   HIV Infections Interventions:   Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets;   Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release) Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   International Maternal Pediatric Adolescent AIDS Clinical Trials Network;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Mental Health (NIMH);   ViiV Hea lthcare Ltd. Not yet recruiting (Source: ClinicalTrials.gov)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2BYsjci

Improving CarE for Community Acquired Pneumonia

Condition:   Pneumonia Childhood Intervention:   Behavioral: Decision Support Sponsors:   Vanderbilt University Medical Center;   National Institute of Allergy and Infectious Diseases (NIAID);   University of Utah;   Intermountain Health Care, Inc. Not yet recruiting (Source: ClinicalTrials.gov)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L7BMRB

HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

Conditions:   Rhinitis, Allergic;   Rhinoconjunctivitis, Allergic Intervention:   Biological: HAL-MRE1 Sponsor:   HAL Allergy Not yet recruiting (Source: ClinicalTrials.gov)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2C09w0n

Amoxicillin Challenge for Penicillin Allergy Diagnosis

Condition:   Penicillin Allergy Intervention:   Diagnostic Test: Penicillin Skin Testing Sponsor:   CHU de Quebec-Universite Laval Not yet recruiting (Source: ClinicalTrials.gov)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L52Vok

Amoxicillin Challenge for Penicillin Allergy Diagnosis

Condition:   Penicillin Allergy Intervention:   Diagnostic Test: Penicillin Skin Testing Sponsor:   CHU de Quebec-Universite Laval Not yet recruiting (Source: ClinicalTrials.gov)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L52Vok

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

Condition:   HIV Infections Interventions:   Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets;   Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release) Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   International Maternal Pediatric Adolescent AIDS Clinical Trials Network;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Mental Health (NIMH);   ViiV Hea lthcare Ltd. Not yet recruiting (Source: ClinicalTrials.gov)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2BYsjci

Improving CarE for Community Acquired Pneumonia

Condition:   Pneumonia Childhood Intervention:   Behavioral: Decision Support Sponsors:   Vanderbilt University Medical Center;   National Institute of Allergy and Infectious Diseases (NIAID);   University of Utah;   Intermountain Health Care, Inc. Not yet recruiting (Source: ClinicalTrials.gov)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L7BMRB

HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

Conditions:   Rhinitis, Allergic;   Rhinoconjunctivitis, Allergic Intervention:   Biological: HAL-MRE1 Sponsor:   HAL Allergy Not yet recruiting (Source: ClinicalTrials.gov)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2C09w0n

WINTON GROUP Ltd Has $243,000 Stake in Exelixis, Inc. (EXEL) - Fairfield Current

exelixis-inc-logo.gif

WINTON GROUP Ltd Has $243,000 Stake in Exelixis, Inc. (EXEL)  Fairfield Current

WINTON GROUP Ltd lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 44.4% during the 3rd quarter, according to the company in its most ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2rofZw2

WINTON GROUP Ltd Has $243,000 Stake in Exelixis, Inc. (EXEL) - Fairfield Current

exelixis-inc-logo.gif

WINTON GROUP Ltd Has $243,000 Stake in Exelixis, Inc. (EXEL)  Fairfield Current

WINTON GROUP Ltd lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 44.4% during the 3rd quarter, according to the company in its most ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2rofZw2

Σάββατο 8 Δεκεμβρίου 2018

How Do You Deal With Uncertainty? Cochlear Implant Users Differ in the Dynamics of Lexical Processing of Noncanonical Inputs

Objectives: Work in normal-hearing (NH) adults suggests that spoken language processing involves coping with ambiguity. Even a clearly spoken word contains brief periods of ambiguity as it unfolds over time, and early portions will not be sufficient to uniquely identify the word. However, beyond this temporary ambiguity, NH listeners must also cope with the loss of information due to reduced forms, dialect, and other factors. A recent study suggests that NH listeners may adapt to increased ambiguity by changing the dynamics of how they commit to candidates at a lexical level. Cochlear implant (CI) users must also frequently deal with highly degraded input, in which there is less information available in the input to recover a target word. The authors asked here whether their frequent experience with this leads to lexical dynamics that are better suited for coping with uncertainty. Design: Listeners heard words either correctly pronounced (dog) or mispronounced at onset (gog) or offset (dob). Listeners selected the corresponding picture from a screen containing pictures of the target and three unrelated items. While they did this, fixations to each object were tracked as a measure of the time course of identifying the target. The authors tested 44 postlingually deafened adult CI users in 2 groups (23 used standard electric only configurations, and 21 supplemented the CI with a hearing aid), along with 28 age-matched age-typical hearing (ATH) controls. Results: All three groups recognized the target word accurately, though each showed a small decrement for mispronounced forms (larger in both types of CI users). Analysis of fixations showed a close time locking to the timing of the mispronunciation. Onset mispronunciations delayed initial fixations to the target, but fixations to the target showed partial recovery by the end of the trial. Offset mispronunciations showed no effect early, but suppressed looking later. This pattern was attested in all three groups, though both types of CI users were slower and did not commit fully to the target. When the authors quantified the degree of disruption (by the mispronounced forms), they found that both groups of CI users showed less disruption than ATH listeners during the first 900 msec of processing. Finally, an individual differences analysis showed that within the CI users, the dynamics of fixations predicted speech perception outcomes over and above accuracy in this task and that CI users with the more rapid fixation patterns of ATH listeners showed better outcomes. Conclusions: Postlingually deafened CI users process speech incrementally (as do ATH listeners), though they commit more slowly and less strongly to a single item than do ATH listeners. This may allow them to cope more flexible with mispronunciations. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and text of this article on the journal's Web site (www.ear-hearing.com). ACKNOWLEDGMENTS: The authors thank Hannah Rigler and Claire Goodwin for assistance with data collection and management, Camille Dunn for assistance with participant recruitment, and Bruce Gantz for support of the overall project. This project was funded by NIH Grants DC008089 awarded to B.M. and DC000242 awarded to Bruce Gantz and B.M. B.M. and K.S.A. conceptualized, designed, and implemented the study. B.M., T.P.E., and K.S.A. analyzed the results. B.M. and K.S.A. wrote the manuscript which all three authors extensively discussed and edited. The authors have no conflicts of interest to disclose. Address for correspondence: Bob McMurray, Department of Psychological and Brain Sciences, University of Iowa, W314 SSH, Iowa City, IA 52242, USA. E-mail: Bob-mcmurray@uiowa.edu Received August 7, 2017; accepted September 10, 2018. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Em3Ccs